SAB Biotherapeutics Inc
SABS
Get informed when a big investor buys or sells
+ FollowMarket Cap$336.65M
Close$
$0.07
98% downside
Current Fair Value
98% downsideOvervalued by 98% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $336.65 Million |
|---|---|
| Enterprise Value | $333.51 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.22 |
| Beta | 0.53 |
| Outstanding Shares | 79,753,100 |
Return
| Return on Equity | -5.95% |
|---|---|
| Return on Assets | -5.36% |
| Return on Invested Capital | -59.32% |
Valuation & Multiples
| P/E Ratio | 2.98 |
|---|---|
| PEG | 2.44 |
| Price to Sales | - |
| Price to Book Ratio | 1.88 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -2.48 |
| Enterprise Value to Net Income | -27 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.28
Average shareholder expectationRevenue Estimate
$125,000
Average shareholder expectationNext Earnings Call
Expected Date
November 13, 2026
EPS Estimate
$-0.27
Average shareholder expectationRevenue Estimate
$125,000
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.3354▲ 33.54% |
|---|---|
| Total Calls | 148,200▲ Infinity% |
| Total Puts | 49,700▲ Infinity% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 358.29%▲ 170.10% |
|---|---|
| Total Invested | $265.01M▲ 94.98% |
| Investors Holding | 81▲ 33.00% |
ESG Score
No data
About SAB Biotherapeutics Inc
81 employeessab biotherapeutics is a clinical-stage biopharmaceutical development company using its novel immunotherapy platform to produce life-saving therapies.